EMA sends more questions to GLP-1 makers over possible risk of suicide, self-harm
The European Medicines Agency’s safety committee on Friday raised more questions for the makers of GLP-1 weight loss drugs after reported cases of thoughts of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.